MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on February 9, 2005; DOI: 10.1124/mol.104.009654


0026-895X/05/6705-1460-1469$20.00
Mol Pharmacol 67:1460-1469, 2005

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Erratum
Right arrow An erratum has been published
Right arrow All Versions of this Article:
mol.104.009654v1
67/5/1460    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Liao, M.
Right arrow Articles by Correia, M. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Liao, M.
Right arrow Articles by Correia, M. A.
ORIGINAL ARTICLE

Vacuolar Degradation of Rat Liver CYP2B1 in Saccharomyces cerevisiae: Further Validation of the Yeast Model and Structural Implications for the Degradation of Mammalian Endoplasmic Reticulum P450 Proteins

Mingxiang Liao, Victor G. Zgoda1, Bernard P. Murray2, and Maria Almira Correia

Departments of Cellular and Molecular Pharmacology, Pharmaceutical Chemistry, and Biopharmaceutical Sciences, and the Liver Center, University of California, San Francisco, San Francisco, California

Abstract

Mammalian hepatic cytochromes P450 (P450s) are endoplasmic reticulum (ER)-anchored hemoproteins with highly variable half-lives. CYP3A4, the dominant human liver drug-metabolizing enzyme, and its rat liver orthologs undergo ubiquitin (Ub)-dependent 26S proteasomal degradation after suicide inactivation or after heterologous expression in Saccharomyces cerevisiae. In contrast, rat liver CYP2C11 is degraded by the vacuolar "lysosomal" pathway when similarly expressed in yeast. The structural determinants that commit P450s to proteasomal or lysosomal degradation are unknown. To further validate S. cerevisiae as a model for exploring mammalian P450 turnover, the degradation of phenobarbital-inducible liver CYP2B1, an enzyme reportedly degraded via the rat hepatic autophagic-lysosomal pathway, was examined in a yeast strain (pep4{Delta}) deficient in vacuolar degradation and its isogenic wild-type control (PEP4). Although CYP2B1 was equivalently expressed in both strains during early logarithmic growth, its degradation was retarded in pep4{Delta} strain, remaining at a level 5-fold higher than that in PEP4 yeast when monitored at the stationary phase. No comparable CYP2B1 stabilization was detected in yeast genetically deficient in the ER Ub-conjugating enzyme Ubc6p or Ubc7p or defective in 19S proteasomal subunit Hrd2p. Thus, as in the rat liver, CYP2B1 is a target of vacuolar/lysosomal rather than proteasomal degradation in yeast, thereby further validating this model for mammalian P450 turnover. It is intriguing that a chimeric protein, CYP2B1-3A4CT, with the CYP3A4 C-terminal heptapeptide grafted onto the CYP2B1 C terminus, was proteasomally degraded after similar expression. Such diversion of CYP2B1 from its predominantly vacuolar degradation suggests that the CYP3A4 heptapeptide could either actively signal its proteasomal degradation or block its vacuolar proteolysis.


Received December 4, 2004; accepted February 8, 2005

Address correspondence to: Dr. M. A. Correia, Department of Cellular and Molecular Pharmacology, Box 0450, University of California, San Francisco, CA 94143-0450. E-mail: mariac{at}itsa.ucsf.edu




This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
C.-M. Lee, B.-Y. Kim, L. Li, and E. T. Morgan
Nitric Oxide-dependent Proteasomal Degradation of Cytochrome P450 2B Proteins
J. Biol. Chem., January 11, 2008; 283(2): 889 - 898.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
M. Liao, S. Faouzi, A. Karyakin, and M. A. Correia
Endoplasmic Reticulum-Associated Degradation of Cytochrome P450 CYP3A4 in Saccharomyces cerevisiae: Further Characterization of Cellular Participants and Structural Determinants
Mol. Pharmacol., June 1, 2006; 69(6): 1897 - 1904.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2005 by the American Society for Pharmacology and Experimental Therapeutics